The economics of venous thromboembolism prophylaxis: a primer for clinicians.

Cost-effectiveness information can help health-system participants make decisions about diagnostic or therapeutic innovations that are more expensive but incrementally safe and effective. However, these analyses cannot help decide whether a less expensive approach is "sufficient" and funds ought to be allocated to other medical issues entirely. At present, formulary committees are commonly determining that medications are "mostly equivalent" in efficacy and safety and choosing individual medications or classes of medications based on cost. Clinicians may not agree with these decisions and will need to understand their rationale. For prophylaxis of venous thromboembolism after hip and knee replacement and hip fracture surgery, many preventive modalities are available with different safety and efficacy profiles and different costs. It is possible to list the important safety and efficacy outcomes of prophylaxis, estimate their incidences and costs, and "model" comparisons of one modality vs another, in order to help decide whether one is preferable.

[1]  B. Eriksson,et al.  Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. , 2002, Archives of internal medicine.

[2]  A. Wood When increased therapeutic benefit comes at increased cost. , 2002, The New England journal of medicine.

[3]  Karen M Kuntz,et al.  Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. , 2002, The New England journal of medicine.

[4]  Bengt I Eriksson,et al.  Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial , 2002, The Lancet.

[5]  B. Eriksson,et al.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. , 2001, The New England journal of medicine.

[6]  B. Eriksson,et al.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. , 2001, The New England journal of medicine.

[7]  A. Turpie,et al.  A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. , 2001, The New England journal of medicine.

[8]  T. Whitsett,et al.  Prolonged Enoxaparin Therapy to Prevent Venous Thromboembolism After Primary Hip or Knee Replacement , 2001, The Journal of bone and joint surgery. American volume.

[9]  J. Heit,et al.  Prevention of venous thromboembolism. , 2001, Clinics in geriatric medicine.

[10]  W. Wade,et al.  Cost effectiveness of deep venous thrombosis prophylaxis after hip fracture. , 2000, American journal of orthopedics.

[11]  J. Danesh,et al.  Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial , 2000, The Lancet.

[12]  H. Buller,et al.  Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. , 2000, Archives of internal medicine.

[13]  R. Friedman,et al.  Cost Analyses of Extended Prophylaxis With Enoxaparin After Hip Arthroplasty , 2000, Clinical orthopaedics and related research.

[14]  W. Bargar,et al.  Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. , 1998, Archives of internal medicine.

[15]  D. Bergqvist,et al.  Cost of Long-Term Complications of Deep Venous Thrombosis of the Lower Extremities: An Analysis of a Defined Patient Population in Sweden , 1997, Annals of Internal Medicine.

[16]  F. Piovella,et al.  [Clinical course and incidence of post-thrombophlebitic syndrome after profound asymptomatic deep vein thrombosis. Results of a transverse epidemiologic study]. , 1997, Minerva cardioangiologica.

[17]  G. Raskob,et al.  Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. , 1997, Archives of internal medicine.

[18]  Paolo Prandoni,et al.  The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[19]  G. Oster,et al.  Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. , 1995, Archives of internal medicine.

[20]  N. Powe,et al.  Economic impact of immunization against rotavirus gastroenteritis. Evidence from a clinical trial. , 1995, Archives of pediatrics & adolescent medicine.

[21]  G. Raskob,et al.  Hemorrhagic complications of anticoagulant treatment. , 1992, Chest.

[22]  J. Heit,et al.  RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group. , 1994, The Journal of bone and joint surgery. American volume.

[23]  G. Oster,et al.  A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. , 1987, JAMA.

[24]  P. W. Willis,et al.  Hemorrhagic complications of anticoagulant therapy. , 1974, Archives of internal medicine.